Page 64 - Drug Class Review

Page 62 of 205
Drug Effectiveness Review Project

placebo 75 60 NR 15% 4% 19 Primary Outcome Measures: Entry to institutionalized care; progression of disability defined by loss of Secondary Outcome Measures: Functional ability measured by the BADLS; NPI; MMSE; compliance Timing of assessments: Baseline and every 12 weeks during treatment No significant difference observed between DON and placebo in rates of institutionalism (9% vs. 14% at 1 year; P = 0.15; 42% vs. 44% at 3 years; P = 0.4)* Progression of disability similar between DON and placebo (13% vs. 19% at 1 year; P = 0.3; 55% No significant difference i

Alzheimer classification: Mild to moderate

Groups similar at baseline: Yes

Health Outcome Measures:

donepezil 76 58 NR 18% 4% 19 2 of 4 basic or 6 of 11 instrumental activities on the BADLS (defined as dropouts); death from AD vs. 53% at 3 years; P = 0.9) Intermediate Outcome Measures: 0.5 – 1.2; P < 0.0001)

• • • • • • •

Final Report Update 1 Authors: AD2000 Collaborative Group Year: 2004 POPULATION CHARACTERISTICS: Median age (years): Sex (% female): Ethnicity: Other germane population qualities: VaD • Parkinsonism • Median baseline MMSE • OUTCOME ASSESSMENT: RESULTS: Alzheimer's Drugs